Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

BUY
$43.23 - $73.83 $3.7 Million - $6.32 Million
85,549 New
85,549 $5.2 Million
Q1 2021

May 11, 2021

SELL
$110.72 - $210.04 $34 Million - $64.5 Million
-307,320 Closed
0 $0
Q4 2020

Feb 09, 2021

BUY
$79.67 - $173.23 $1.14 Million - $2.47 Million
14,279 Added 4.87%
307,320 $47.1 Million
Q3 2020

Nov 12, 2020

BUY
$78.5 - $100.64 $1.42 Million - $1.82 Million
18,124 Added 6.59%
293,041 $24.5 Million
Q2 2020

Aug 14, 2020

SELL
$38.5 - $76.05 $633,594 - $1.25 Million
-16,457 Reduced 5.65%
274,917 $20.2 Million
Q1 2020

May 14, 2020

BUY
$33.68 - $62.53 $301,099 - $559,018
8,940 Added 3.17%
291,374 $12.4 Million
Q4 2019

Feb 14, 2020

SELL
$36.68 - $73.13 $2.74 Million - $5.45 Million
-74,587 Reduced 20.89%
282,434 $17.2 Million
Q3 2019

Nov 14, 2019

BUY
$40.99 - $52.56 $14.6 Million - $18.8 Million
357,021 New
357,021 $14.6 Million
Q3 2018

Nov 14, 2018

SELL
$44.35 - $65.71 $10 Million - $14.8 Million
-225,970 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$42.62 - $73.59 $9.63 Million - $16.6 Million
225,970 New
225,970 $13.3 Million

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.23B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Lord, Abbett & Co. LLC Portfolio

Follow Lord, Abbett & Co. LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lord, Abbett & Co. LLC with notifications on news.